Astellas's antibody conjugate for renal cancer enters the clinic
This article was originally published in Scrip
Executive Summary
Astellas's US-based anticancer antibody subsidiary, Agensys, has begun clinical trials with an antibody-drug conjugate (ADC) for metastatic renal cancer, building on an alliance with Seattle Genetics which was expanded last year.